

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

NCT06080789

Status	RECRUITING
Phase	Phase 2
Sponsor	Panafina, Inc.
Enrollment	36 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosis of acute pancreatitis
- Predicted severe acute pancreatitis, based on protocol defined criteria
- Lack of clinically meaningful improvement from status at admission, at the discretion of Investigator, at the time of randomization
- Suitable for EUS-guided study drug administration procedure

Exclusion (6)

- Confirmed severe acute pancreatitis as defined by the Revised Atlanta Classification of Acute Pancreatitis (ie, Persistent \[> 48 hours\] organ failure, per Modified Marshall Score), prior to randomization
- Anticipated discharge from hospital within 48 hours of randomization
- More than 30% pancreatic necrosis on screening CECT or MRI
- History of previous pancreatic necrosis, including necrosectomy
- History of calcific chronic pancreatitis
- ... and 1 more (see full listing online)

Locations (15 total)

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Keck Hospital of USC and LA County Hospital, Los Angeles, California, United States
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
... and 12 more locations